Apr 3, 2025 | Press Releases
To be presented at 11th Annual Immunotherapy of Cancer (ITOC) Conference in Munich, Germany Marlborough, Massachusetts–(Newsfile Corp. – April 3, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biotechnology company...
Mar 31, 2025 | Press Releases
Continues advancing clinical trial for INSTASYL siRNA lead product candidate PH-7623rd Cohort now fully enrolled in on-going clinical studyMarlborough, Massachusetts–(Newsfile Corp. – March 31, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a...
Mar 10, 2025 | Press Releases
Interim Results from clinical study for cutaneous carcinomas presented at Late-Breaking Research SessionMarlborough, Massachusetts–(Newsfile Corp. – March 10, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company...
Mar 5, 2025 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – March 5, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the...
Feb 26, 2025 | Press Releases
Registration Link for Presentation and live Q&A to take place, Wednesday March 5, 2025 at 12:00 pm ESTMarlborough, Massachusetts–(Newsfile Corp. – February 26, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) a clinical-stage biotechnology...
Feb 20, 2025 | Press Releases
Marlborough, Massachusetts–(Newsfile Corp. – February 20, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make...
